#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small cell lung cancer extensive stage Mitochondrial myopathy Amyotrophic lateral sclerosis Arterial disorder Chordoma Cystic fibrosis lung Congenital ectodermal dysplasia Aspergillus infection Osteomyelitis Liver transplant rejection Propionic acidaemia Breast angiosarcoma metastatic Immune-mediated enterocolitis Ewing's sarcoma recurrent Hypophosphatasia More trials…

    Learn about Rare Diseases

    Familial haemophagocytic lymphohistiocytosis – Life with Disease Friedreich’s ataxia – Basic Information Propionic acidaemia Pemphigoid – Trials in Disease Congenital hypotransferrinaemia – Trials in Disease Glycogen storage disease type V – Trials in Disease VEXAS syndrome Lymphangioma – Diagnostics Optic glioma – Life with Disease Erdheim-Chester disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Magnesium Stearate Jk06 Psma-11 Donepezil Chlorphenamine Maleate Icosapent Ethyl Dazucorilant Ursodoxicoltaurine Selexipag Etidronate Disodium Mps-103 Egl-001 Etifoxine Hydrochloride Istradefylline Nusinersen [18F]Fapi-74 Fipaxalparant Lactose Monohydrate Ovolecithin L-Glutamic Acid More therapies…

    Learn about Your Condition

    Perineal injury Myocarditis post infection Neurofibrosarcoma Cardiac failure acute Pharyngeal cancer stage III CDKL5 deficiency disorder Spinal osteoarthritis Hyperhidrosis Gestational diabetes HER2 negative breast cancer Hydrocephalus Aortic disorder Dyskinesia Encephalopathy neonatal Deafness neurosensory More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Mantle cell lymphoma recurrent

  • A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma recurrent
    • Mantle cell lymphoma refractory
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Glofitamab
    • Lenalidomide
    France Italy Spain Sweden

  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • Follicular lymphoma stage II
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • BGB-16673
    • Mosunetuzumab
    Germany Italy Poland

  • Safety Study of Sonrotoclax and Zanubrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

    Recruiting

    1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma recurrent
    • Mantle cell lymphoma refractory
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Zanubrutinib
    France

  • Study on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma recurrent
    • Mantle cell lymphoma refractory
    Investigated Drugs:
    • Loncastuximab Tesirine
    • Bendamustine Hydrochloride
    • Cytarabine
    Italy

  • Study on KTE-X19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma Responding Partially to Ibrutinib

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma recurrent
    • Mantle cell lymphoma refractory
    • Mantle cell lymphoma
    Investigated Drugs:
    • Anhydrous Cyclophosphamide
    • Brexucabtagene Autoleucel
    • Fludarabine
    Italy

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!